ARDX
Ardelyx, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-19
Figures on this page computed 2026-11-08 12:48 UTC
Last close
2.99USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-02-19
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-19
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
- 10-K for 2025, filed 2026-02-19
- 10-K for 2025, filed 2026-02-19
- 10-K for 2025, filed 2026-02-19
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-19
- 10-Q for 2025, filed 2026-11-03
-15.1%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
- 10-K for 2025, filed 2026-02-19
- 10-K for 2025, filed 2026-02-19
-10.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
- 10-K for 2025, filed 2026-02-19
- 10-K for 2025, filed 2026-02-19
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
- 10-K for 2025, filed 2026-02-19
- 10-Q for 2025, filed 2026-11-03
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth121.9%61 of 100, above its sector
- Returns on capital-36.9%25 of 100, above its sector
- Margins90.3%46 of 100, above its sector
- Price4.2x39 of 100, above its sector
- Safety4.3152 of 100, at its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
What it sells, to whom
lens 8 of 9What it sells
1Where it sells it
3Who it sells it to
1Each band is a share of itself. A segment and a place are two cuts of the same revenue, so they are never added together.
1 segments, 3 places and 1 named customers, each as the filer published it.
1 segments, 3 places and 1 named customers, each as the filer published it.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-19
Reportable Segment407,320,000
- Source
- filed
- Statement
- segments
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
UNITED STATES377,808,000
- Source
- filed
- Statement
- revenue_mix
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
Asia Pacific29,170,000
- Source
- filed
- Statement
- revenue_mix
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
North America342,000
- Source
- filed
- Statement
- revenue_mix
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013
- Reported in
- USD
BioRidge Pharma, LLC65.9%
- Source
- filed
- Statement
- concentration
- Fiscal year
- 2025
- Accession
- 0001437402-26-000013